<VariationArchive VariationID="2025240" VariationName="NC_000002.12:g.218812223dup" VariationType="Duplication" Accession="VCV002025240" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-20" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2084443" VariationID="2025240">
      <GeneList>
        <Gene Symbol="CYP27A1" FullName="cytochrome P450 family 27 subfamily A member 1" GeneID="1593" HGNC_ID="HGNC:2605" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2q35</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="218782147" stop="218815293" display_start="218782147" display_stop="218815293" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="219646471" stop="219680015" display_start="219646471" display_stop="219680015" Strand="+" />
          </Location>
          <OMIM>606530</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000002.12:g.218812223dup</Name>
      <CanonicalSPDI>NC_000002.12:218812220:GGG:GGGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>2q35</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="218812220" stop="218812221" display_start="218812220" display_stop="218812221" variantLength="1" positionVCF="218812220" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="219676943" stop="219676944" display_start="219676943" display_stop="219676944" variantLength="1" positionVCF="219676943" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.219676946dup" Assembly="GRCh37">
            <Expression>NC_000002.11:g.219676946dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.218812223dup" Assembly="GRCh38">
            <Expression>NC_000002.12:g.218812223dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007959.1" sequenceAccession="NG_007959" sequenceVersion="1" change="g.35475dup">
            <Expression>NG_007959.1:g.35475dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000002.12:g.218812223dup AND Cholestanol storage disease" Accession="RCV002853006" Version="2">
        <ClassifiedConditionList TraitSetID="1177">
          <ClassifiedCondition DB="MedGen" ID="C0238052">Cholestanol storage disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-10-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-10-10" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10775536</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26937392</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9392430</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1177" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="873" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Cerebral cholesterinosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">CTX: Cerebrotendinous xanthomatosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Cholestanol storage disease</ElementValue>
                <XRef ID="63246000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cerebrotendinous Xanthomatosis</ElementValue>
                <XRef ID="NBK1409" DB="GeneReviews" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CTX</ElementValue>
                <XRef Type="MIM" ID="213700" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Cerebrotendinous xanthomatosis (CTX) is a lipid storage disease characterized by infantile-onset diarrhea, childhood-onset cataract, adolescent- to young adult-onset tendon xanthomas, and adult-onset progressive neurologic dysfunction (dementia, psychiatric disturbances, pyramidal and/or cerebellar signs, dystonia, atypical parkinsonism, peripheral neuropathy, and seizures). Chronic diarrhea from infancy and/or neonatal cholestasis may be the earliest clinical manifestation. In approximately 75% of affected individuals, cataracts are the first finding, often appearing in the first decade of life. Xanthomas appear in the second or third decade; they occur on the Achilles tendon, the extensor tendons of the elbow and hand, the patellar tendon, and the neck tendons. Xanthomas have been reported in the lung, bones, and central nervous system. Some individuals show cognitive impairment from early infancy, whereas the majority have normal or only slightly impaired intellectual function until puberty; dementia with slow deterioration in intellectual abilities occurs in the third decade in more than 50% of individuals. Neuropsychiatric symptoms such as behavioral changes, hallucinations, agitation, aggression, depression, and suicide attempts may be prominent. Pyramidal signs (i.e., spasticity) and/or cerebellar signs almost invariably become evident between ages 20 and 30 years. The biochemical abnormalities that distinguish CTX from other conditions with xanthomas include high plasma and tissue cholestanol concentration, normal-to-low plasma cholesterol concentration, decreased chenodeoxycholic acid (CDCA), increased concentration of bile alcohols and their glyconjugates, and increased concentrations of cholestanol and apolipoprotein B in cerebrospinal fluid.</Attribute>
                <XRef ID="NBK1409" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5622" />
                <XRef ID="5622" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301583</ID>
                <ID Source="BookShelf">NBK1409</ID>
              </Citation>
              <XRef ID="909" DB="Orphanet" />
              <XRef ID="C0238052" DB="MedGen" />
              <XRef ID="MONDO:0008948" DB="MONDO" />
              <XRef Type="MIM" ID="213700" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5919031" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="17342468|MedGen:C0238052" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003230287" DateUpdated="2024-02-20" DateCreated="2023-02-07" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-10-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9392430</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10775536</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26937392</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant has not been reported in the literature in individuals affected with CYP27A1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu150Glyfs*31) in the CYP27A1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CYP27A1 are known to be pathogenic (PMID: 9392430, 10775536, 26937392).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CYP27A1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.219676943_219676944insG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0238052" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5919031" TraitType="Disease" MappingType="XRef" MappingValue="C0238052" MappingRef="MedGen">
        <MedGen CUI="C0238052" Name="Cholestanol storage disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

